Qi-Dong You

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6504691/publications.pdf

Version: 2024-02-01

227 papers	7,679 citations	50276 46 h-index	79698 73 g-index
232 all docs	232 docs citations	232 times ranked	8181 citing authors

#	Article	IF	Citations
1	The Keap1â€“Nrf2â€“ARE Pathway As a Potential Preventive and Therapeutic Target: An Update. Medicinal Research Reviews, 2016, 36, 924-963.	10.5	562
2	Discovery of Potent Keap1â€–Nrf2 Proteinâ€–Protein Interaction Inhibitor Based on Molecular Binding Determinants Analysis. Journal of Medicinal Chemistry, 2014, 57, 2736-2745.	6.4	193
3	Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway. European Journal of Medicinal Chemistry, 2018, 146, 251-259.	5.5	186
4	Gambogic Acid Induces Apoptosis and Regulates Expressions of Bax and Bcl-2 Protein in Human Gastric Carcinoma MGC-803 Cells. Biological and Pharmaceutical Bulletin, 2004, 27, 998-1003.	1.4	176
5	Gambogic Acid Inhibits Proliferation of Human Lung Carcinoma SPC-A1 Cells in Vivo and in Vitro and Represses Telomerase Activity and Telomerase Reverse Transcriptase mRNA Expression in the Cells. Biological and Pharmaceutical Bulletin, 2004, 27, 1769-1774.	1.4	174
6	Anti-hepatitis B virus activity of wogonin in vitro and in vivo. Antiviral Research, 2007, 74, 16-24.	4.1	158
7	Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Letters, 2007, 256, 259-266.	7.2	133
8	Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions. Journal of Medicinal Chemistry, 2020, 63, 1798-1822.	6.4	117
9	Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown. Journal of Medicinal Chemistry, 2020, 63, 4644-4654.	6.4	102
10	Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. Life Sciences, 2006, 78, 1238-1245.	4.3	99
11	Gambogic acid inhibits angiogenesis through suppressing vascular endothelial growth factor-induced tyrosine phosphorylation of KDR/Flk-1. Cancer Letters, 2007, 258, 80-89.	7.2	95
12	Prodrug strategy for cancer cell-specific targeting: A recent overview. European Journal of Medicinal Chemistry, 2017, 139, 542-563.	5.5	95
13	CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-ÎºB activation. Redox Biology, 2019, 26, 101266.	9.0	93
14	General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice. Acta Pharmacologica Sinica, 2004, 25, 769-74.	6.1	90
15	Drug resistance associates with activation of Nrf2 in <scp>MCF</scp>â€/<scp>DOX</scp> cells, and wogonin reverses it by downâ€regulating Nrf2â€mediated cellular defense response. Molecular Carcinogenesis, 2013, 52, 824-834.	2.7	88
16	Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Proteinâ€“Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions. Journal of Medicinal Chemistry, 2016, 59, 10837-10858.	6.4	88
17	Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIFâ€1Î± and glycolysis, by inhibiting PI3K/Akt signaling pathway. Molecular Carcinogenesis, 2014, 53, E107-18.	2.7	87
18	Targeting Stimulator of Interferon Genes (STING): A Medicinal Chemistry Perspective. Journal of Medicinal Chemistry, 2020, 63, 3785-3816.	6.4	85

#	Article	IF	Citations
19	Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells. Molecular Cancer Therapeutics, 2008, 7, 3298-3305.	4.1	84
20	An inhibitor of the Keap1-Nrf2 protein-protein interaction protects NCM460 colonic cells and alleviates experimental colitis. Scientific Reports, 2016, 6, 26585.	3.3	82
21	Reactive oxygen species accumulation contributes to gambogic acid-induced apoptosis in human hepatoma SMMC-7721 cells. Toxicology, 2009, 260, 60-67.	4.2	81
22	Oroxylin A induced apoptosis of human hepatocellular carcinoma cell line HepG2 was involved in its antitumor activity. Biochemical and Biophysical Research Communications, 2006, 351, 521-527.	2.1	79
23	Inhibition of glioblastoma growth and angiogenesis by gambogic acid: An in vitro and in vivo study. Biochemical Pharmacology, 2008, 75, 1083-1092.	4.4	77
24	Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway. Biochemical Pharmacology, 2014, 92, 220-234.	4.4	76
25	Structureâ€“Activity and Structureâ€“Property Relationship and Exploratory in Vivo Evaluation of the Nanomolar Keap1â€“Nrf2 Proteinâ€“Protein Interaction Inhibitor. Journal of Medicinal Chemistry, 2015, 58, 6410-6421.	6.4	76
26	Regulation of Nrf2 by phosphorylation: Consequences for biological function and therapeutic implications. Free Radical Biology and Medicine, 2021, 168, 129-141.	2.9	74
27	Studies on the toxicity of gambogic acid in rats. Journal of Ethnopharmacology, 2008, 117, 433-438.	4.1	73
28	Repression of telomerase reverse transcriptase mRNA and hTERT promoter by gambogic acid in human gastric carcinoma cells. Cancer Chemotherapy and Pharmacology, 2006, 58, 434-443.	2.3	69
29	Discovery of a Novel Series of Quinolone and Naphthyridine Derivatives as Potential Topoisomerase I Inhibitors by Scaffold Modification. Journal of Medicinal Chemistry, 2009, 52, 5649-5661.	6.4	66
30	The Anticancer Activities of Wogonin in Murine Sarcoma S180 both in Vitro and in Vivo. Biological and Pharmaceutical Bulletin, 2006, 29, 1132-1137.	1.4	62
31	Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. Journal of Molecular Graphics and Modelling, 2008, 26, 1160-1168.	2.4	60
32	Wogonin Induced Calreticulin/Annexin A1 Exposure Dictates the Immunogenicity of Cancer Cells in a PERK/AKT Dependent Manner. PLoS ONE, 2012, 7, e50811.	2.5	59
33	Wogonin potentiates the antitumor effects of low dose 5-fluorouracil against gastric cancer through induction of apoptosis by down-regulation of NF-kappaB and regulation of its metabolism. Toxicology Letters, 2010, 197, 201-210.	0.8	58
34	Toxicological Studies of Gambogic Acid and its Potential Targets in Experimental Animals. Basic and Clinical Pharmacology and Toxicology, 2006, 99, 178-184.	2.5	57
35	Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer. Science Advances, 2019, 5, eaax2277.	10.3	57
36	Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis. Journal of Molecular Medicine, 2008, 86, 1367-1377.	3.9	56

#	Article	IF	Citations
37	Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells. Biochemistry and Cell Biology, 2012, 90, 718-730.	2.0	56
38	Involvement of bax/bcl-2 in wogonin-induced apoptosis of human hepatoma cell line SMMC-7721. Anti-Cancer Drugs, 2006, 17, 797-805.	1.4	55
39	A novel structure-based virtual screening model for the hERG channel blockers. Biochemical and Biophysical Research Communications, 2007, 355, 889-894.	2.1	55
40	Garcinia Xanthones as Orally Active Antitumor Agents. Journal of Medicinal Chemistry, 2013, 56, 276-292.	6.4	55
41	Novel proteinâ€“protein interaction inhibitor of Nrf2â€“Keap1 discovered by structure-based virtual screening. MedChemComm, 2014, 5, 93-98.	3.4	55
42	Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency. European Journal of Medicinal Chemistry, 2018, 143, 1578-1589.	5.5	55
43	5-(3,4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1,2,4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson's disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress. Free Radical Biology and Medicine, 2019, 134, 288-303.	2.9	54
44	Anti-invasive effect of gambogic acid in MDA-MB-231 human breast carcinoma cells. Biochemistry and Cell Biology, 2008, 86, 386-395.	2.0	50
45	Wogonin induced differentiation and G1 phase arrest of human U-937 leukemia cells via PKCÎ´ phosphorylation. European Journal of Pharmacology, 2008, 591, 7-12.	3.5	50
46	3-(2-Oxo-2-phenylethylidene)-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one (compound 1), a novel potent Nrf2/ARE inducer, protects against DSS-induced colitis via inhibiting NLRP3 inflammasome. Biochemical Pharmacology, 2016, 101, 71-86.	4.4	50
47	Wogonin inhibits LPS-induced tumor angiogenesis via suppressing PI3K/Akt/NF-ÎºB signaling. European Journal of Pharmacology, 2014, 737, 57-69.	3.5	49
48	Posttranscriptional regulation of the telomerase hTERT by gambogic acid in human gastric carcinoma 823 cells. Cancer Letters, 2008, 262, 223-231.	7.2	48
49	Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structureâ€“Activity Relationship Study. Journal of Medicinal Chemistry, 2015, 58, 5419-5436.	6.4	48
50	The pharmacophore hypotheses of IKr potassium channel blockers: novel class III antiarrhythmic agents. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4771-4777.	2.2	46
51	2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1). European Journal of Medicinal Chemistry, 2014, 82, 56-67.	5.5	46
52	Binding thermodynamics and kinetics guided optimization of potent Keap1â€“Nrf2 peptide inhibitors. RSC Advances, 2015, 5, 85983-85987.	3.6	43
53	Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology, 2009, 256, 135-140.	4.2	41
54	Studies on chemical structure modification and biology of a natural product, Gambogic acid (I): Synthesis and biological evaluation of oxidized analogues of gambogic acid. European Journal of Medicinal Chemistry, 2009, 44, 2611-2620.	5.5	41

#	Article	IF	Citations
55	High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity. European Journal of Medicinal Chemistry, 2016, 124, 480-489.	5.5	41
56	Small-Molecule Modulators of the Hypoxia-Inducible Factor Pathway: Development and Therapeutic Applications. Journal of Medicinal Chemistry, 2019, 62, 5725-5749.	6.4	41
57	Wogonin induces the granulocytic differentiation of human NB4 promyelocytic leukemia cells and up-regulates phospholipid scramblase 1 gene expression. Cancer Science, 2008, 99, 689-695.	3.9	40
58	3-Aroylmethylene-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-ones as Potent Nrf2/ARE Inducers in Human Cancer Cells and AOM-DSS Treated Mice. Journal of Medicinal Chemistry, 2013, 56, 7925-7938.	6.4	40
59	Optimization and biological evaluation of celastrol derivatives as Hsp90â€“Cdc37 interaction disruptors with improved druglike properties. Bioorganic and Medicinal Chemistry, 2016, 24, 5431-5439.	3.0	39
60	Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5. European Journal of Medicinal Chemistry, 2016, 118, 1-8.	5.5	38
61	Toxicological studies of wogonin in experimental animals. Phytotherapy Research, 2009, 23, 417-422.	5.8	37
62	Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile. European Journal of Medicinal Chemistry, 2017, 129, 27-40.	5.5	37
63	Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1Î± pathway. European Journal of Medicinal Chemistry, 2017, 137, 45-62.	5.5	37
64	p62 as a therapeutic target for tumor. European Journal of Medicinal Chemistry, 2020, 193, 112231.	5.5	37
65	Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening. European Journal of Medicinal Chemistry, 2014, 79, 399-412.	5.5	36
66	Wogonin inhibits H2O2-induced angiogenesis via suppressing PI3K/Akt/NF-ÎºB signaling pathway. Vascular Pharmacology, 2014, 60, 110-119.	2.1	36
67	Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction. European Journal of Medicinal Chemistry, 2017, 136, 63-73.	5.5	36
68	Current Development of ROS-Modulating Agents as Novel Antitumor Therapy. Current Cancer Drug Targets, 2017, 17, 122-136.	1.6	36
69	Synthesis and evaluation of (Â±)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1). Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1244-1248.	2.2	35
70	Click Chemistry-Based Discovery of [3-Hydroxy-5-(1H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia. Journal of Medicinal Chemistry, 2018, 61, 5332-5349.	6.4	35
71	Predicting the potency of hERG K+ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models. Journal of Molecular Modeling, 2012, 18, 1023-1036.	1.8	34
72	Wogonin induced cytotoxicity in human hepatocellular carcinoma cells by activation of unfolded protein response and inactivation of <scp>AKT</scp>. Hepatology Research, 2013, 43, 890-905.	3.4	34

#	Article	IF	Citations
73	Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells. Oncotarget, 2014, 5, 8188-8201.	1.8	34
74	Design, synthesis and biological evaluation of novel 3-substituted 4-anilino-coumarin derivatives as antitumor agents. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 867-874.	2.2	33
75	Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERÎ±/VEGFR-2 ligands with anti-breast cancer activity. European Journal of Medicinal Chemistry, 2018, 150, 783-795.	5.5	33
76	Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2018, 61, 11280-11297.	6.4	33
77	Discovery of a Potent Grp94 Selective Inhibitor with Anti-Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis. Journal of Medicinal Chemistry, 2018, 61, 9513-9533.	6.4	33
78	One-Pot Synthesis of Tetrahydrobenzo[b]pyran Derivatives Catalyzed by Amines in Aqueous Media. Organic Preparations and Procedures International, 2009, 41, 77-82.	1.3	32
79	Subchronic toxicity and plasma pharmacokinetic studies on wogonin, a natural flavonoid, in Beagle dogs. Journal of Ethnopharmacology, 2009, 124, 257-262.	4.1	32
80	Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90. Journal of Medicinal Chemistry, 2016, 59, 10498-10519.	6.4	32
81	Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Inhibition: An Emerging Strategy in Cancer Therapy. Journal of Medicinal Chemistry, 2019, 62, 3840-3856.	6.4	32
82	Targeting the HSP90â€“CDC37â€“kinase chaperone cycle: A promising therapeutic strategy for cancer. Medicinal Research Reviews, 2022, 42, 156-182.	10.5	32
83	Polar Recognition Group Study of Keap1-Nrf2 Proteinâ€“Protein Interaction Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 835-840.	2.8	31
84	Recent progress in the development of small molecule Nrf2 activators: a patent review (2017-present). Expert Opinion on Therapeutic Patents, 2020, 30, 209-225.	5.0	31
85	Wogonin Suppresses Melanoma Cell B16-F10 Invasion and Migration by Inhibiting Ras-Medicated Pathways. PLoS ONE, 2014, 9, e106458.	2.5	30
86	Design, Synthesis, and Structureâ€“Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Proteinâ€“Protein Interaction Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 11149-11168.	6.4	30
87	A systematic molecular dynamics approach to the study of peptide Keap1â€“Nrf2 proteinâ€“protein interaction inhibitors and its application to p62 peptides. Molecular BioSystems, 2016, 12, 1378-1387.	2.9	29
88	Discovery of a Potent Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1â€“Nrf2) Proteinâ€“Protein Interaction Inhibitor with Natural Proline Structure as a Cytoprotective Agent against Acetaminophen-Induced Hepatotoxicity. Journal of Medicinal Chemistry, 2019, 62, 6796-6813.	6.4	29
89	Synthesis and biological evaluation of 2,3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERÎ± and VEGFR-2. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2129-2133.	2.2	28
90	Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors. Molecular Cancer Therapeutics, 2008, 7, 1007-1012.	4.1	27

#	Article	IF	Citations
91	Synthesis and bioevaluation of a series of Î±-pyrone derivatives asÂpotent activators of Nrf2/ARE pathway (part I). European Journal of Medicinal Chemistry, 2013, 66, 364-371.	5.5	27
92	Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERÎ± and VEGFR-2 as anti-breast cancer agents. European Journal of Medicinal Chemistry, 2016, 118, 328-339.	5.5	27
93	An updated patent review of anticancer Hsp90 inhibitors (2013-present). Expert Opinion on Therapeutic Patents, 2021, 31, 67-80.	5.0	27
94	Pharmacophore identification of KSP inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 722-726.	2.2	26
95	Investigation of the intermolecular recognition mechanism between the E3 ubiquitin ligase Keap1 and substrate based on multiple substrates analysis. Journal of Computer-Aided Molecular Design, 2014, 28, 1233-1245.	2.9	25
96	Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation. Bioorganic and Medicinal Chemistry, 2016, 24, 1006-1013.	3.0	25
97	An NAD(P)H:Quinone Oxidoreductase 1 Responsive and Self-Immolative Prodrug of 5-Fluorouracil for Safe and Effective Cancer Therapy. Organic Letters, 2018, 20, 3635-3638.	4.6	25
98	Medicinal chemistry of metal chelating fragments in metalloenzyme active sites: A perspective. European Journal of Medicinal Chemistry, 2019, 165, 172-197.	5.5	25
99	Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective. Journal of Medicinal Chemistry, 2021, 64, 10537-10556.	6.4	25
100	Beyond Proteolysis-Targeting Chimeric Molecules: Designing Heterobifunctional Molecules Based on Functional Effectors. Journal of Medicinal Chemistry, 2022, 65, 8091-8112.	6.4	25
101	Studies on chemical modification and biology of a natural product, gambogic acid (II): Synthesis and bioevaluation of gambogellic acid and its derivatives from gambogic acid as antitumor agents. European Journal of Medicinal Chemistry, 2010, 45, 4343-4353.	5.5	24
102	Design and discovery of 4-anilinoquinazoline ureas as multikinase inhibitors targeting BRAF, VEGFR-2 and EGFR. MedChemComm, 2013, 4, 979.	3.4	24
103	Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification. Bioorganic and Medicinal Chemistry, 2016, 24, 6102-6108.	3.0	24
104	Discovery and Optimization of Small Molecules Targeting the Proteinâ€“Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer. Journal of Medicinal Chemistry, 2020, 63, 1281-1297.	6.4	24
105	Design and bio-evaluation of indole derivatives as potent Kv1.5 inhibitors. Bioorganic and Medicinal Chemistry, 2013, 21, 6466-6476.	3.0	23
106	Structure-activity and structure-property relationships of novel Nrf2 activators with a 1,2,4-oxadiazole core and their therapeutic effects on acetaminophen (APAP)-induced acute liver injury. European Journal of Medicinal Chemistry, 2018, 157, 1376-1394.	5.5	23
107	A hydrogen peroxide responsive prodrug of Keap1-Nrf2 inhibitor for improving oral absorption and selective activation in inflammatory conditions. Redox Biology, 2020, 34, 101565.	9.0	23
108	Recent Advances in the Discovery of HIF-1Î±-p300/CBP Inhibitors as Anti-Cancer Agents. Mini-Reviews in Medicinal Chemistry, 2018, 18, 296-309.	2.4	23

#	Article	IF	Citations
109	Characterization of binding site of closed-state KCNQ1 potassium channel by homology modeling, molecular docking, and pharmacophore identification. Biochemical and Biophysical Research Communications, 2005, 332, 677-687.	2.1	22
110	Modeling the binding modes of Kv1.5 potassium channel and blockers. Journal of Molecular Graphics and Modelling, 2008, 27, 178-187.	2.4	22
111	Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 1236-1240.	2.8	22
112	Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)â€“WDR5 interaction. Bioorganic and Medicinal Chemistry, 2016, 24, 6109-6118.	3.0	22
113	2-Substituted 3,7,8-trimethylnaphtho[1,2- b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer. European Journal of Medicinal Chemistry, 2017, 138, 616-629.	5.5	22
114	Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5â€“Mixed Lineage Leukemia 1 Proteinâ€“Protein Interaction for the Treatment of MLL Fusion Leukemia. Journal of Medicinal Chemistry, 2021, 64, 8221-8245.	6.4	22
115	Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy. European Journal of Medicinal Chemistry, 2021, 220, 113539.	5.5	22
116	Kinesin spindle protein Inhibitors as anticancer agents. Expert Opinion on Therapeutic Patents, 2006, 16, 1517-1532.	5.0	21
117	Synthesis and pHâ€induced phase transition behavior of PAA/PVA nanogels in aqueous media. Journal of Applied Polymer Science, 2009, 111, 358-362.	2.6	21
118	Studies on gambogic acid (IV): Exploring structureâ€“activity relationship with IÎºB kinase-beta (IKKÎ²). European Journal of Medicinal Chemistry, 2012, 51, 110-123.	5.5	21
119	Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions. European Journal of Medicinal Chemistry, 2020, 207, 112734.	5.5	21
120	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2). Bioorganic and Medicinal Chemistry, 2013, 21, 5339-5354.	3.0	20
121	Discovery and identification of Cdc37-derived peptides targeting the Hsp90â€“Cdc37 proteinâ€“protein interaction. RSC Advances, 2015, 5, 96138-96145.	3.6	20
122	Developmental toxicity and genotoxicity studies of wogonin. Regulatory Toxicology and Pharmacology, 2011, 60, 212-217.	2.7	19
123	Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core. Bioorganic and Medicinal Chemistry, 2016, 24, 3540-3547.	3.0	19
124	Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors. Bioorganic Chemistry, 2019, 91, 103181.	4.1	19
125	Modulation of protein fate decision by small molecules: targeting molecular chaperone machinery. Acta Pharmaceutica Sinica B, 2020, 10, 1904-1925.	12.0	19
126	Docking studies on kinesin spindle protein inhibitors: an important cooperative â€˜minor binding pocketâ€™ which increases the binding affinity significantly. Journal of Molecular Modeling, 2007, 13, 987-992.	1.8	18

#	Article	IF	Citations
127	The Interactions Between hERG Potassium Channel and Blockers. Current Topics in Medicinal Chemistry, 2009, 9, 330-338.	2.1	18
128	Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: Introduction of an additional carboxyl group at the C-2 position of quinoline. European Journal of Medicinal Chemistry, 2015, 105, 145-155.	5.5	18
129	Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells. Journal of Pharmacy and Pharmacology, 2010, 60, 1459-1463.	2.4	17
130	Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90ÂC-terminal inhibitors. European Journal of Medicinal Chemistry, 2017, 141, 1-14.	5.5	17
131	Recent developments of small molecules targeting RNA m6A modulators. European Journal of Medicinal Chemistry, 2020, 196, 112325.	5.5	17
132	Highly Stereoselective Nucleophilic Addition of Difluoromethylâ€2â€pyridyl Sulfone to Sugar Lactones and Efficient Synthesis of Fluorinated 2â€Ketoses. European Journal of Organic Chemistry, 2014, 2014, 6150-6154.	2.4	16
133	Design, Synthesis, and Initial Evaluation of Affinity-Based Small-Molecule Probes for Fluorescent Visualization and Specific Detection of Keap1. Journal of Medicinal Chemistry, 2016, 59, 7305-7310.	6.4	16
134	Optimization and bioevaluation of Cdc37-derived peptides: An insight into Hsp90-Cdc37 protein-protein interaction modulators. Bioorganic and Medicinal Chemistry, 2017, 25, 233-240.	3.0	16
135	Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kΐ. Bioorganic and Medicinal Chemistry, 2018, 26, 4537-4543.	3.0	16
136	Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Journal of Medicinal Chemistry, 2020, 63, 10045-10060.	6.4	16
137	Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope. Acta Pharmaceutica Sinica B, 2022, 12, 2990-3005.	12.0	16
138	Research Toward Potassium Channels on Tumor Progression. Current Topics in Medicinal Chemistry, 2009, 9, 322-329.	2.1	15
139	Design, synthesis and biological evaluation of novel histone deacetylase inhibitors based on virtual screening. Acta Pharmaceutica Sinica B, 2011, 1, 240-247.	12.0	15
140	Facile synthesis of 2,5,7-trisubstituted oxazolo[5,4-d]pyrimidines via copper-catalyzed intramolecular Câ€“O bond formation. Tetrahedron, 2012, 68, 4248-4251.	1.9	15
141	Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function. Current Drug Targets, 2017, 18, 1572-1585.	2.1	15
142	Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective. Journal of Medicinal Chemistry, 2022, 65, 8065-8090.	6.4	15
143	Convenient Synthesis of Wogonin, A Flavonoid Natural Product with Extensive Pharmacological Activity. Organic Preparations and Procedures International, 2009, 41, 327-330.	1.3	14
144	Microwave-Assisted Simple Synthesis of Substituted 4-Quinolone Derivatives. Synthetic Communications, 2009, 39, 4375-4383.	2.1	14

#	Article	IF	Citations
145	Synthesis and Evaluation of Gambogic Acid Derivatives as Antitumor Agents. Part III. Chemistry and Biodiversity, 2013, 10, 73-85.	2.1	14
146	Synthesis and evaluation of N -(benzofuran-5-yl)aromaticsulfonamide derivatives as novel HIF-1 inhibitors that possess anti-angiogenic potential. Bioorganic and Medicinal Chemistry, 2017, 25, 1737-1746.	3.0	14
147	Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1138-1142.	2.2	14
148	Strategies for Targeting Serine/Threonine Protein Phosphatases with Small Molecules in Cancer. Journal of Medicinal Chemistry, 2021, 64, 8916-8938.	6.4	14
149	A Facile and Scaleable Synthesis of 3-O-Decladinose-6-methyl-10,11-dehydrate-erythromycin-3-one-2â€˜-acetate, an Important Intermediate for Ketolide Synthesis. Organic Process Research and Development, 2006, 10, 446-449.	2.7	13
150	Strategies for atrial fibrillation therapy: focusing onI_{Kur}potassium channel. Expert Opinion on Therapeutic Patents, 2007, 17, 1443-1456.	5.0	13
151	Microwave-Assisted Esterification of Diverse Carboxylic Acids and Chiral Amino Acids. Synthetic Communications, 2008, 38, 4107-4115.	2.1	13
152	Total synthesis of aldehyde-containing Garcinia natural products isomorellin and gaudichaudione A. Tetrahedron, 2011, 67, 4774-4779.	1.9	13
153	Kinesin spindle protein inhibitors in cancer: a patent review (2008 â€“ present). Expert Opinion on Therapeutic Patents, 2013, 23, 1547-1560.	5.0	13
154	Pharmacophore Mapping for Kv1.5 Potassium Channel Blockers. QSAR and Combinatorial Science, 2009, 28, 59-71.	1.4	12
155	Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6284-6288.	2.2	12
156	Studies on Chemical Structure Modification and Structureï£¿Activity Relationship of Derivatives of Gambogic Acid at C(39). Chemistry and Biodiversity, 2012, 9, 1579-1590.	2.1	12
157	Structureâ€“activity relationship of Garcinia xanthones analogues: Potent Hsp90 inhibitors with cytotoxicity and antiangiogenesis activity. Bioorganic and Medicinal Chemistry, 2016, 24, 4626-4635.	3.0	12
158	Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy. Bioorganic and Medicinal Chemistry, 2018, 26, 356-365.	3.0	12
159	Structure-guided design and synthesis of isoflavone analogs of GW4064 with potent lipid accumulation inhibitory activities. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3726-3730.	2.2	12
160	PREPARATION OF N-UNSUBSTITUTED THIOAMIDES BY A MODIFIED WILLGERODT-KINDLER REACTION. Organic Preparations and Procedures International, 1991, 23, 435-438.	1.3	11
161	Molecular hybridization, synthesis, and biological evaluation of novel chroman IKr and IKs dual blockers. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1477-1480.	2.2	11
162	Microwave-Assisted Efficient and Green Synthesis of Hydroxyxanthone in Water. Synthetic Communications, 2012, 42, 2952-2958.	2.1	11

#	Article	IF	Citations
163	Synthesis and Biological Evaluation of Novel Oxazolo[5,4â€d]pyrimidines as Potent VEGFRâ€2 Inhibitors. Chemistry and Biodiversity, 2015, 12, 528-537.	2.1	11
164	Small-molecule inhibitors of HIF-PHD2: a valid strategy to renal anemia treatment in clinical therapy. MedChemComm, 2016, 7, 1271-1284.	3.4	11
165	3-(1H-Benzo[d]imidazol-6-yl)-5-(4-fluorophenyl)-1,2,4-oxadiazole (DDO7232), a Novel Potent Nrf2/ARE Inducer, Ameliorates DSS-Induced Murine Colitis and Protects NCM460 Cells against Oxidative Stress via ERK1/2 Phosphorylation. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-16.	4.0	11
166	Pharmacophore Identification of Hydroxamate HDAC 1 Inhibitors. Chinese Journal of Chemistry, 2009, 27, 557-564.	4.9	10
167	Photoactivatable Prolyl Hydroxylase 2 Inhibitors for Stabilizing the Hypoxia-Inducible Factor with Light. Journal of Medicinal Chemistry, 2019, 62, 7583-7588.	6.4	10
168	Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy. Drug Discovery Today, 2020, 25, 1873-1882.	6.4	10
169	Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with inÂvivo antitumor activity. European Journal of Medicinal Chemistry, 2021, 223, 113677.	5.5	10
170	CPUYJ039, a newly synthesized benzimidazole-based compound, is proved to be a novel inducer of apoptosis in HCT116 cells with potent KSP inhibitory activity. Journal of Pharmacy and Pharmacology, 2011, 63, 1462-1469.	2.4	9
171	Structureâ€Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on it for Novel Inhibitors. Molecular Informatics, 2011, 30, 579-592.	2.5	9
172	Synthesis and Antiâ€tumor Evaluation of Novel Câ€37 Modified Derivatives of Gambogic Acid. Chinese Journal of Chemistry, 2012, 30, 1083-1091.	4.9	9
173	Design, synthesis and biological evaluation of novel androst-3,5-diene-3-carboxylic acid derivatives as inhibitors of 5Î±-reductase type 1 and 2. Steroids, 2017, 124, 29-34.	1.8	9
174	Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction. European Journal of Medicinal Chemistry, 2020, 188, 112027.	5.5	9
175	Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity. Current Topics in Medicinal Chemistry, 2016, 16, 1843-1854.	2.1	9
176	Design, Synthesis and Evaluation of Tetrahydroisoquinolines as New Kinesin Spindle Protein Inhibitors. Chemical and Pharmaceutical Bulletin, 2009, 57, 567-571.	1.3	8
177	Structureâ€Based Virtual Screening and Electrophysiological Evaluation of New Chemotypes of K_v1.5 Channel Blockers. ChemMedChem, 2010, 5, 1353-1358.	3.2	8
178	Synthesis and Antiâ€tumor Evaluation of Bâ€ring Modified Caged Xanthone Analogues of Gambogic Acid. Chinese Journal of Chemistry, 2012, 30, 35-42.	4.9	8
179	1,2-trans-1-Dihydroxyboryl benzyl S-glycoside as glycosyl donor. Carbohydrate Research, 2014, 398, 45-49.	2.3	8
180	Discovery of NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibitors with novel chemical scaffolds by shape-based virtual screening combined with cascade docking. RSC Advances, 2015, 5, 49471-49479.	3.6	8

#	Article	IF	Citations
181	Design, synthesis, and initial evaluation of affinity-based small molecular probe for detection of WDR5. Bioorganic Chemistry, 2018, 76, 380-385.	4.1	8
182	Design, synthesis and bioevaluation of inhibitors targeting HSP90-CDC37 protein-protein interaction based on a hydrophobic core. European Journal of Medicinal Chemistry, 2021, 210, 112959.	5.5	8
183	Discovery of a covalent inhibitor of heat shock protein 90 with antitumor activity that blocks the co-chaperone binding via C-terminal modification. Cell Chemical Biology, 2021, 28, 1446-1459.e6.	5.2	8
184	Effects of a novel class III antiarrhythmic agent, CPUY11018, on rat atrial fibrillation. Drug Development Research, 2010, 71, 303-312.	2.9	7
185	Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments. Molecules, 2016, 21, 879.	3.8	7
186	Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 3891-3899.	3.0	7
187	Design, synthesis and biological evaluation of novel 2-methoxyestradiol analogs as dual selective estrogen receptor modulators (SERMs) and antiangiogenic agents. European Journal of Medicinal Chemistry, 2017, 139, 390-400.	5.5	7
188	Lipid accumulation inhibitory activities of novel isoxazole-based chenodeoxycholic acids: Design, synthesis and preliminary mechanism study. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2879-2884.	2.2	7
189	Target Fishing Reveals a Novel Mechanism of 1,2,4-Oxadiazole Derivatives Targeting Rpn6, a Subunit of 26S Proteasome. Journal of Medicinal Chemistry, 2022, 65, 5029-5043.	6.4	7
190	Discovery of Clinical Candidate NTQ1062 as a Potent and Bioavailable Akt Inhibitor for the Treatment of Human Tumors. Journal of Medicinal Chemistry, 2022, 65, 8144-8168.	6.4	7
191	Hydrogen Peroxide Inducible JAK3 Covalent Inhibitor: Prodrug for the Treatment of RA with Enhanced Safety Profile. ACS Medicinal Chemistry Letters, 2020, 11, 2182-2189.	2.8	6
192	Methods for the Discovery and Identification of Small Molecules Targeting Oxidative Stress-Related Proteinâ€"Protein Interactions: An Update. Antioxidants, 2022, 11, 619.	5.1	6
193	Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis. European Journal of Medicinal Chemistry, 2022, 238, 114423.	5.5	6
194	In silico binding characteristics between human histamine H1 receptor and antagonists. Journal of Molecular Modeling, 2010, 16, 1529-1537.	1.8	5
195	De novo design of novel DNAâ€"gyrase inhibitors based on 2D molecular fingerprints. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4166-4171.	2.2	5
196	An improved and scalable synthesis of N-(5-(4-cyanophenyl)-3-hydroxypicolinoyl)glycine, a promising PHD2 inhibitor for the treatment of anemia. Tetrahedron Letters, 2015, 56, 5017-5019.	1.4	5
197	Agonist of stimulator of interferon genes as antitumor agents: a patent review (2008-2020). Expert Opinion on Therapeutic Patents, 2021, 31, 563-584.	5.0	5
198	Discovery of 3,5-Dimethyl-4-Sulfonyl-1H-Pyrrole-Based Myeloid Cell Leukemia 1 Inhibitors with High Affinity, Selectivity, and Oral Bioavailability. Journal of Medicinal Chemistry, 2021, 64, 11330-11353.	6.4	5

#	Article	IF	Citations
199	Application of cation-Ï€ interactions in enzyme-substrate binding: Design, synthesis, biological evaluation, and molecular dynamics insights of novel hydrophilic substrates for NQO1. European Journal of Medicinal Chemistry, 2021, 221, 113515.	5.5	5
200	Design and synthesis of Grp94 selective inhibitors based on Phe199 induced fit mechanism and their anti-inflammatory effects. European Journal of Medicinal Chemistry, 2021, 223, 113604.	5.5	5
201	USE OF POLYPHOSPHORIC ACID IN THE HYDROLYSIS OF CHROMONE ESTERS. Synthetic Communications, 2002, 32, 709-714.	2.1	4
202	Cascade Reaction and Synthesis of Bicyclo[2,2,2]octenones. Chinese Journal of Chemistry, 2008, 26, 363-367.	4.9	4
203	Pharmacophore Guided 3Dâ€QSAR CoMFA Analysis of Amino Substituted Nitrogen Heterocycle Ureas as KDR Inhibitors. QSAR and Combinatorial Science, 2009, 28, 1524-1536.	1.4	4
204	Comparison of Electron Captureâ€"Atmospheric Pressure Chemical Ionization and Electrospray Ionization for the Analysis of Gambogic Acid and its Main Circulating Metabolite in Dog Plasma. European Journal of Mass Spectrometry, 2010, 16, 605-617.	1.0	4
205	The Multiple Ion Channel Blocker CPUY11018 Prevents Aconitine-Induced Arrhythmias. Drug Development Research, 2012, 73, 214-221.	2.9	4
206	Antiarrhythmic efficacy of CPUY102122, a multiple ion channel blocker, on rabbits with ischemia/reperfusion injury. Pharmacological Reports, 2014, 66, 1022-1030.	3.3	4
207	Synthesis, biological evaluation, and molecular docking of ropivacaine analogs as local anesthetic agents. Medicinal Chemistry Research, 2018, 27, 954-965.	2.4	4
208	Synthesis, sciatic nerve block activity evaluation and molecular docking of fluoro-substituted lidocaine analogs as local anesthetic agents. Medicinal Chemistry Research, 2019, 28, 1783-1795.	2.4	4
209	Novel Dualâ€Siteâ€Binding Neuraminidase Inhibitor from Virtual Screening by Pharmacophore and Molecular Dynamics Methods. Chinese Journal of Chemistry, 2012, 30, 1735-1740.	4.9	3
210	Synthesis and biological evaluation of isoflavone amide derivatives with antihyperlipidemic and preadipocyte antiproliferative activities. Bioorganic and Medicinal Chemistry, 2015, 23, 4428-4433.	3.0	3
211	Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5Î±-androst-17Î²-amide derivatives as dual 5Î±-reductase inhibitors and androgen receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4212-4217.	2.2	3
212	Lipid reducing activity of novel cholic acid (CA) analogs: Design, synthesis and preliminary mechanism study. Bioorganic Chemistry, 2018, 80, 396-407.	4.1	3
213	An efficient synthesis of an optically active (-)-(3R, 4R,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 187 Td (5R)-4-(1-hydroxyl-isopro 665-668.	1.3	2
214	A Pharmacophore Modeling Study of Drugs Inducing Cardiotoxic Side Effects. Chinese Journal of Chemistry, 2008, 26, 2125-2132.	4.9	2
215	Structure-activity Relationship of Gambogic Acid. Chinese Journal of Natural Medicines, 2008, 6, 37-42.	1.3	2
216	Novel approach to stereoselective synthesis of (E)/(Z)-(N-acyl-oxazolidinone)-eneglycinates. Research on Chemical Intermediates, 2015, 41, 749-760.	2.7	2

#	Article	IF	Citations
217	Betulinic acid acetate, an antiproliferative natural product, suppresses client proteins of heat shock protein pathways through a CDC37-binding mechanism. RSC Advances, 2016, 6, 42537-42544.	3.6	2
218	The First Total Synthesis of the Diastereoisomers A and B ofTuxpanolidefromPerymenium hintonii. Journal of the Chinese Chemical Society, 2006, 53, 349-358.	1.4	1
219	Antiarrhythmic Efficacy of <scp>CPUY</scp>11018 Under Pathological Conditions. Drug Development Research, 2013, 74, 194-202.	2.9	1
220	A General and Facile Synthesis of Novel Polysubstituted Quinazolinâ€4(3H)â€ones. Journal of Heterocyclic Chemistry, 2013, 50, 169-174.	2.6	1
221	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-3. Molecules, 2018, 23, 1596.	3.8	1
222	HSP90 Inhibitors Blocking Multiple Oncogenic Signaling Pathways for the Treatment of Cancer. Heat Shock Proteins, 2019, , 397-429.	0.2	1
223	An affinity prediction approach for the ligand of E3 ligase Cbl-b and an insight into substrate binding pattern. Bioorganic and Medicinal Chemistry, 2021, 38, 116130.	3.0	1
224	CONVENIENT AND RAPID PREPARATION OF INDENE DIMERS FROM INDENES OR INDANOLS. Organic Preparations and Procedures International, 2006, 38, 490-494.	1.3	0
225	Pharmacophore Modeling and in Silico Screening Studies to Design Potential KDR Kinase Inhibitors. Chinese Journal of Chemistry, 2011, 29, 1107-1113.	4.9	0
226	Potassium Channel Blockers as Antiarrhythmic Agents. , 2011, , 117-147.		0
227	Discovery and Development of Hepatitis C Virus Inhibitors Targeting the NS5A Protein. Mini-Reviews in Medicinal Chemistry, 2015, 15, 553-581.	2.4	0